Published in Mol Med Rep on December 18, 2014
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol (2012) 14.55
Liver biopsy. Hepatology (2009) 7.61
Classification of chronic viral hepatitis: a need for reassessment. J Hepatol (1991) 5.23
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int (2008) 4.16
Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology (2009) 4.03
Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A (2005) 2.70
GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol (2005) 2.70
Reactivation of hepatitis B. Hepatology (2009) 2.46
[The guideline of prevention and treatment for chronic hepatitis B (2010 version)]. Zhonghua Gan Zang Bing Za Zhi (2011) 2.20
GP73, a novel Golgi-localized protein upregulated by viral infection. Gene (2000) 1.96
Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology (2002) 1.68
Vaccination against hepatitis B: the Chinese experience. Chin Med J (Engl) (2009) 1.67
Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut (2010) 1.67
Disease- and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol (2004) 1.65
SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology (2005) 1.55
Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol (2007) 1.49
Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic (2007) 1.48
AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol (2010) 1.44
Liver biopsy findings in chronic hepatitis B. Hepatology (2009) 1.18
Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int J Cancer (2011) 1.15
Leptin represses matrix metalloproteinase-1 gene expression in LX2 human hepatic stellate cells. J Hepatol (2006) 1.15
Decreased survival and hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2). Int J Clin Exp Pathol (2008) 1.15
N-linked glycosylation of the liver cancer biomarker GP73. J Cell Biochem (2008) 1.14
Increased Golgi protein 73 expression in hepatocellular carcinoma tissue correlates with tumor aggression but not survival. J Gastroenterol Hepatol (2011) 1.13
Hepatocyte GP73 expression in Wilson disease. J Hepatol (2009) 0.96
A study of diagnostic value of golgi protein GP73 and its genetic assay in primary hepatic carcinoma. Technol Cancer Res Treat (2011) 0.96
Golgi protein 73(GP73), a useful serum marker in liver diseases. Clin Chem Lab Med (2011) 0.91
Evaluation of the patient with hepatitis B. Hepatology (2009) 0.88
Golgi protein 73 as a biomarker of hepatocellular cancer: development of a quantitative serum assay and expression studies in hepatic and extrahepatic malignancies. Hepatology (2009) 0.86
GP73 and liver disease: a (Golgi) complex enigma. Am J Gastroenterol (2004) 0.86
Serum gp73 is also a biomarker for diagnosing cirrhosis in population with chronic HBV infection. Clin Biochem (2014) 0.83